Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases — Stella

Home/Hypertensive Nephropathy/ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

View on ClinicalTrials.gov

Recruiting

Back to Hypertensive Nephropathy trials

ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Egypt

British Centre For Regenerative medicine BCRMED Global, Giza, GZ

Key details

Phase

Post-approval study

Sponsor

Ace Cells Lab Limited

Enrollment target

~300 participants

Started

September 2025

Primary completion

August 2026

Age range

18 Years – 80 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.